| Michael Carson Hodges, MD | |
|
3634 Cape Center Dr, Fayetteville, NC 28304 | |
| (910) 485-6470 | |
| (910) 485-8198 |
| Full Name | Michael Carson Hodges |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 31 Years |
| Location | 3634 Cape Center Dr, Fayetteville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821062522 | NPI | - | NPPES |
| 89136WF | Medicaid | NC | |
| 136WF | Other | NC | BCBS OF NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 9500616 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cape Fear Valley Medical Center | Fayetteville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cape Fear Cardiology Associates Pa | 3476539883 | 11 |
News Archive
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology 2018 Congress, being held October 19-23, 2018, in Munich, Germany.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
A diagnosis of pancreatic cancer is often a death sentence because current chemotherapies have little impact on the disease.
The present randomized clinical trial attempted to study if colchicine will effectively hasten recovery and reduce COVID-19 associated hospitalizations or death.
A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).
› Verified 8 days ago
| Entity Name | Cape Fear Cardiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831165802 PECOS PAC ID: 3476539883 Enrollment ID: O20040626000211 |
News Archive
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology 2018 Congress, being held October 19-23, 2018, in Munich, Germany.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
A diagnosis of pancreatic cancer is often a death sentence because current chemotherapies have little impact on the disease.
The present randomized clinical trial attempted to study if colchicine will effectively hasten recovery and reduce COVID-19 associated hospitalizations or death.
A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Carson Hodges, MD 3634 Cape Center Dr, Fayetteville, NC 28304 Ph: (910) 485-6470 | Michael Carson Hodges, MD 3634 Cape Center Dr, Fayetteville, NC 28304 Ph: (910) 485-6470 |
News Archive
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology 2018 Congress, being held October 19-23, 2018, in Munich, Germany.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
A diagnosis of pancreatic cancer is often a death sentence because current chemotherapies have little impact on the disease.
The present randomized clinical trial attempted to study if colchicine will effectively hasten recovery and reduce COVID-19 associated hospitalizations or death.
A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).
› Verified 8 days ago
Kenneth Melton, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 557 Sandhurst Dr, Fayetteville, NC 28304 Phone: 910-484-8114 Fax: 910-484-1564 | |
Kenneth Russell Manning, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1638 Owen Dr, Fayetteville, NC 28304 Phone: 910-609-6910 Fax: 910-609-5219 | |
San San Wai, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2300 Ramsey St, Va Medical Center, Fayetteville, NC 28301 Phone: 910-488-2120 | |
Dr. Sabena Johnson, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2300 Ramsey St, Fayetteville, NC 28301 Phone: 910-488-2120 | |
Dr. Stephen S Logue, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1843 Quiet Cv, Fayetteville, NC 28304 Phone: 910-483-8080 Fax: 910-483-3258 | |
David Tat, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1601 Owen Dr, Fayetteville, NC 28304 Phone: 910-678-0100 Fax: 910-678-0110 | |
Dr. Ghanshyam Pradyumna Dwivedi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1778 Metromedical Dr, Fayetteville, NC 28304 Phone: 910-483-4680 Fax: 910-484-2704 |